A rating of 22 puts Crispr Therapeutics AG (CRSP) near the bottom of the Biotechnology industry according to InvestorsObserver. Crispr Therapeutics AG's score of 22 means it scores higher than 22% of stocks in the industry. Crispr Therapeutics AG also received an overall rating of 28, putting it above 28% of all stocks. Biotechnology is ranked 101 out of the 148 industries.
What do These Ratings Mean?
Finding the best stocks can be tricky. It isn’t easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObserver’s tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.
This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.
What's Happening With Crispr Therapeutics AG Stock Today?
Crispr Therapeutics AG (CRSP) stock is trading at $114.14 as of 11:17 AM on Tuesday, May 4, a decline of -$8.67, or -7.06% from the previous closing price of $122.81. The stock has traded between $114.00 and $120.78 so far today. Volume today is less active than usual. So far 878,577 shares have traded compared to average volume of 1,483,817 shares.